Cited by — Abstract No: 305 PROMINENT: AN OPEN-LABEL, RANDOMIZED PHASE 3 TRIAL OF FELZARTAMAB IN PRIMARY MEMBRANOUS NEPHROPATHY | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Abstract No: 305 PROMINENT: AN OPEN-LABEL, RANDOMIZED PHASE 3 TRIAL OF FELZARTAMAB IN PRIMARY MEMBRANOUS NEPHROPATHY.
No admitted local citation edges point to this work yet.
